Latest news with #Selectra
The Journal
06-05-2025
- Business
- The Journal
Irish households pay 30% more for electricity than the average European
IRISH HOUSEHOLDS ARE currently paying the third-highest costs in Europe for electricity. A recent Eurostat study found that Irish household customers are paying approximately 30% more (around €347 more) per year for electricity than the average EU home. For electricity costs, Germany is the costliest, followed by Denmark and then Ireland, according to Eurostat data. Prices are also much higher in Ireland than those in non-EU countries such as Iceland and Norway. Estimated annual bills in Ireland remain 61% higher for electricity and 90% higher for gas than they were before the steep rise in energy prices that began in December 2020. According to comparison site Selectra , the average annual electricity cost for Irish homeowners is €1,556. Gas prices in Ireland are also elevated, ranking as the sixth highest in the EU, at nearly 10% above the EU average. Advertisement This means Irish households are paying around €125 more per year for their gas compared to other EU countries. Daragh Cassidy, Head of Communications for said that the latest figures 'aren't surprising'. 'We've a relatively small and dispersed population with too much one-off housing so the costs for the upkeep of our electricity network are very high on a per capita basis,' Cassidy said. He added that the rapid growth of the population here and the increase in the number of data centres in recent years also 'hasn't helped'. According to the latest CSO data, data centres consume over a fifth (21%) of all electricity in Ireland. 'This is putting pressure on the grid. And in recent years we've had to procure high cost, high emission, emergency gas generation to plug the gap between electricity demand and supply,' Cassidy explained. Ireland also has a 'weakly connected grid', according to Cassidy, who said that the country is 'quite isolated' – meaning that Ireland can't import a huge amount of cheaper electricity from abroad. 'Though the interconnector we're building with France will hopefully improve things when it comes online in 2027 as it will allow us to tap into generally cheaper French electricity,' Cassidy said. Readers like you are keeping these stories free for everyone... A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation. Learn More Support The Journal
Yahoo
19-03-2025
- Business
- Yahoo
Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
Release Date: March 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Inovio Pharmaceuticals Inc (NASDAQ:INO) has resolved the manufacturing issue with the single-use array component of the Selectra device, which is crucial for their BLA submission for INO 3,107. The company plans to begin the BLA submission process in mid-2025, with the goal of FDA acceptance by the end of the year. Clinical data for INO 3,107 shows significant and durable clinical benefits, with a reduction in the need for surgeries for RRP patients. Inovio Pharmaceuticals Inc (NASDAQ:INO) has made progress in developing their DNA encoded monoclonal antibody technology, showing durable in vivo production in humans. The company has reduced operational expenses by 22% from 2023 to 2024, demonstrating effective cost management. Inovio Pharmaceuticals Inc (NASDAQ:INO) experienced delays in resolving the manufacturing issue, which took longer than initially expected. The company reported a net loss of $107.3 million for the full year of 2024, indicating ongoing financial challenges. Cash and cash equivalents decreased significantly from $145.3 million in 2023 to $94.1 million in 2024, raising concerns about financial sustainability. The company needs to initiate a confirmatory trial before the BLA submission, which could pose additional challenges and delays. There is uncertainty regarding the long-term epidemiology and market size for RRP, as vaccination rates and disease prevalence could impact future demand. Warning! GuruFocus has detected 6 Warning Signs with INO. Q: For the BLA submission request for INO 3,107, do you need to meet with the FDA, or is it just a written request? A: (Dr. Mike Sumner, Chief Medical Officer) We held a pre-BLA meeting with the FDA before resolving the single-use array issue. We had good alignment on the remaining modules, so we don't need another meeting. We plan to request the rolling submission in mid-2025. Q: Regarding the stability test for the device, is it a single test or a series of tests, and who conducts them? A: (Dr. Mike Sumner, Chief Medical Officer) We need to repeat several tests for verification, which are conducted by an external testing house. This includes external certification required for our BLA. Q: Can you provide insights into the durability of in vivo antibody production from the DMAP technology? A: (Dr. Jackie Shea, President and CEO) The DMAP technology has shown durable antibody production, with levels stable for 72 weeks. We are exploring inducible or repressible promoters for future trials to control expression. Q: What are the commercial assumptions for INO 3,107, and how do you see it positioned against competitors? A: (Dr. Jackie Shea, President and CEO) INO 3,107 has a strong product profile with durable efficacy and a patient-centric regimen. It can be administered in a doctor's office without the need for surgery during dosing. We are confident in its competitive positioning. Q: How should we think about the redosing strategy for INO 3,107, and what is the long-term outlook for the RRP market? A: (Dr. Mike Sumner, Chief Medical Officer) We are still deciding on the redosing strategy, aiming to reduce surgeries to zero. The RRP market remains significant, especially in adults, as vaccination rates are not yet high enough to impact adult cases significantly. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
